Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

M Company (MMM) reports better-than-expected Q2 2025 results, raises full-year guidance, driven by growth in all business ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

The Q2 earnings reporting cycle is underway with the peak of the season still to come. It will begin mid-July with the report from JPMorgan Chase & Company (NYSE: JPM), making now a good time to ...

The expectation is for Q2 earnings to increase by +5% from the same period last year on +4% higher revenues. This will be a material deceleration from the growth trend of recent quarters and will ...

Strength, Questions and 2025 Outlook ...

Pfizer: Competitive Advantages Still Exist, but Signs of Erosion Lead Us to Lower Our Valuation We’ve also reduced the firm’s moat rating from wide to narrow.

Stock indexes closed higher on Wall Street, enough to nudge the S&P 500 and the Nasdaq composite to more records. The S&P 500 ...